GlobalData projects the total revenue from branded infectious diseases (ID) drugs and vaccines...
- Gilead led the global infectious diseases space in 2017
- AAD 2018: strong Phase IIb results for upadacitinib in atopic dermatitis
- ORIC Pharma to advance ORIC-101 against treatment-resistant cancers
- Takeda and Wave Life Sciences to develop neurological treatments
- AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?
Gilead led the global infectious diseases space in 2017
GlobalData projects the total revenue from branded infectious diseases (ID) drugs and vaccines to surpass $75bn in 2017.
AAD 2018: strong Phase IIb results for upadacitinib in atopic dermatitis
On 17 February, primary results from a Phase IIb clinical trial assessing the use of AbbVie’s upadacitinib in adult patients with moderate to severe atopic dermatitis (AD) was presented at the 76th Annual American Academy of Dermatology (AAD) meeting.
Phase I Study of Bromodomain Inhibitor OTX015
This white paper describes the methods and findings of a dose-escalation, open-label, pharmacokinetic, Phase I study of bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma.
ORIC Pharma to advance ORIC-101 against treatment-resistant cancers
Oncology company ORIC Pharmaceuticals has completed a $50m Series C preferred stock financing to support advancement of its ORIC-101 against treatment-resistant solid tumours, as well as continued progress on mechanisms of resistance in cancer.
Takeda and Wave Life Sciences to develop neurological treatments
Takeda Pharmaceutical has signed a research, development and commercial collaboration and multi-programme option agreement with Wave Life Sciences to create new antisense oligonucleotides as treatments for genetically defined neurological diseases.
Charles Ischi Presents Modular Tablet Hardness Tester LAB.line P-Series
Charles Ischi’s versatile laboratory tablet hardness testers in the P-Series offer you the latest technology, space-saving design and maximum flexibility.
AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?
At the 76th annual meeting of the American Academy of Dermatology, Johnson & Johnson (J&J) released a cost per responder analysis of their interleukin 23 subunit alpha (IL-23A) inhibitor Tremfya (guselkumab) compared with Novartis’ IL-17 inhibitor Cosentyx (secukinumab) and Eli Lilly’s IL-17A inhibitor Taltz (ixekizumab) for the treatment of moderate to severe plaque psoriasis (PsO).
Biogen continues to dominate the neurology market
Among the top 10 players in neurology, Biogen is the only company that generated more than 50% of its total sales from neurology products, the vast majority of which are derived from its broad multiple sclerosis (MS) portfolio, including Tecfidera, Avonex, and Tysabri.
Zealand Pharma and UniQuest to develop new peptide therapeutics
Zealand Pharma and The University of Queensland’s (UQ) commercialisation company UniQuest are set to collaborate to identify novel peptide therapeutics inspired by venoms as potential new treatments for gastrointestinal diseases.
UK study finds genetic cause behind drug-resistant typhoid strain
Scientists at the Wellcome Sanger Institute, UK, have discovered the genetic cause associated with a strain of typhoid that has become resistant to five classes of antibiotics.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.